Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for folic acid
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on folic acid or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on folic acid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Fortification of wheat and maize flour with folicacid for population health outcomes. Folate is a B-vitamin required for DNA synthesis, methylation, and cellular division. Wheat and maize (corn) flour are staple crops consumed widely throughout the world and have been fortified with folicacid in over 80 countries to prevent neural tube defects. Folicacid fortification may be an effective strategy to improve folate status and other health outcomes in the overall population.To evaluate (...) the health benefits and safety of folicacid fortification of wheat and maize flour (i.e. alone or in combination with other micronutrients) on folate status and health outcomes in the overall population, compared to wheat or maize flour without folicacid (or no intervention).We searched the following databases in March and May 2018: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and MEDLINE In Process, Embase, CINAHL, Web of Science (SSCI, SCI), BIOSIS, Popline, Bibliomap, TRoPHI
2019CochraneControlled trial quality: predicted high
Effect of high dose folicacid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. To determine the efficacy of high dose folicacid supplementation for prevention of pre-eclampsia in women with at least one risk factor: pre-existing hypertension, prepregnancy diabetes (type 1 or 2), twin pregnancy, pre-eclampsia in a previous pregnancy, or body mass index ≥35.Randomised, phase III, double blinded international (...) , multicentre clinical trial.70 obstetrical centres in five countries (Argentina, Australia, Canada, Jamaica, and UK).2464 pregnant women with at least one high risk factor for pre-eclampsia were randomised between 2011 and 2015 (1144 to the folicacid group and 1157 to the placebo group); 2301 were included in the intention to treat analyses.Eligible women were randomised to receive either daily high dose folicacid (four 1.0 mg oral tablets) or placebo from eight weeks of gestation to the end of week 16
Folicacid Top results for folicacid - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for folicacid The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms
FolicAcid Supplementation for the Prevention of Neural Tube Defects: US Preventive Services Task Force Recommendation Statement. Neural tube defects are among the most common major congenital anomalies in the United States and may lead to a range of disabilities or death. Daily folicacid supplementation in the periconceptional period can prevent neural tube defects. However, most women do not receive the recommended daily intake of folate from diet alone.To update the 2009 US Preventive (...) Services Task Force (USPSTF) recommendation on folicacid supplementation in women of childbearing age.In 2009, the USPSTF reviewed the effectiveness of folicacid supplementation in women of childbearing age for the prevention of neural tube defects in infants. The current review assessed new evidence on the benefits and harms of folicacid supplementation.The USPSTF assessed the balance of the benefits and harms of folicacid supplementation in women of childbearing age and determined that the net
How does smoking, alcohol use, folicacid, maternal obesity and timing of antenatal care in pregnancy vary by socioeconomic status or age of mother? Knowledge & Library Services (KLS) Evidence Briefing How does smoking, alcohol use, folicacid, maternal obesity and timing of antenatal care in pregnancy vary by socioeconomic status or age of mother? Nicola Pearce-Smith November 29 th 2017 How does smoking, alcohol use, folicacid, maternal obesity and timing of antenatal care in pregnancy vary (...) by socioeconomic status or age of mother? KLS Evidence Briefing November 29 th 2017 Question This briefing summarises the evidence on five risk factors in pregnancy (use of alcohol, smoking, maternal obesity, folicacid supplementation and timing of antenatal care) for women of different ages and socioeconomic status (SES), from Jan 2008 to Nov 2017. Key messages ? advanced maternal age (AMA) of 35yrs or older was often associated with an increased risk of stillbirth, low birthweight, preterm birth, Caesarean
FolicAcid for the Prevention of Neural Tube Defects: Preventive Medication Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Women who are planning or capable of pregnancy The USPSTF recommends that all women who are planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folicacid. A Population Women who are planning or capable of pregnancy Recommendation Take a daily (...) supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folicacid. Grade: A Risk Assessment All women of childbearing age are at risk of having a pregnancy affected by neural tube defects. Some factors increase this risk, including a personal or family history of neural tube defects, use of particular antiseizure medications, maternal diabetes, obesity, and mutations in folate-related enzymes. Preventive Medication Folicacid is the synthetic form of folate, a water-soluble B vitamin. Folicacid
The evaluation of serum homocysteine, folicacid, and vitamin B12 in patients complicated with preeclampsia Increased plasma homocysteine may be associated with adverse pregnancy outcomes, such as preeclampsia. The aim of this study was to determine the plasma homocysteine, serum folate, and vitamin B12 levels in preeclamptic pregnant women.This case-control study was conducted in 2016 in Ahwaz on 51 pregnant women with preeclampsia and 51 healthy pregnant women of the same gestational age, who (...) served as controls. The case group also was subdivided into severe and non-severe preeclampsia. Patients' data were collected through a questionnaire and medical records. Serum homocysteine, folicacid, and vitamin B12 were analyzed using chemiluminescent assay. The results were compared between two groups. Statistical analyses were done using IBM-SPSS 20.0. A Kolmogorov-Smirnov test, independent samples t-test, Mann-Whitney test, and Chi-square test were used for data analysis.No different
Effect of FolicAcid therapy on Homocysteine Level in patients with Atherosclerosis or Buergerâ€™s Disease and in Healthy individuals: A clinical trial Hyperhomocysteinemia is considered a risk factor for atherosclerosis and some other vascular diseases such as Buerger's disease.The aim of this study was to measure the Homocysteine levels in 3 different groups of participants (Buerger's disease, atherosclerosis patients, and healthy cases) and determine the therapeutic effect of folicacid (...) and after 12 weeks of folicacid (5mg/day) therapy. The data analysis used fo data analysis was a Chi square and t-test or their non-parametrical equivalents for data analysis by means of Statistical Package for the Social Sciences (SPSS) version 16.The homocysteine levels were found to be significantly higher in patients with Buerger's disease as compared to other groups before treatment with folicacid (Buerger = 21.8 ± 8.5 Mm/L, atherosclerosis = 17.3 ± 6.9, healthy = 13.8 ± 3.1; p < 0.001). After
Efficacy of FolicAcid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial The efficacy of folicacid therapy on renal outcomes has not been previously investigated in populations without folicacid fortification.To test whether treatment with enalapril and folicacid is more effective in slowing renal function decline than enalapril alone across a spectrum of renal function at baseline from normal to moderate chronic kidney (...) disease (CKD) among Chinese adults with hypertension.In this substudy of eligible China Stroke Primary Prevention Trial (CSPPT), 15 104 participants with an estimated glomerular filtration rate (eGFR) 30 mL/min/1.73 m2 or greater, including 1671 patients with CKD, were recruited from 20 communities in Jiangsu province in China.Participants were randomized to receive a single tablet daily containing 10 mg enalapril and 0.8 mg folicacid (n = 7545) or 10 mg enalapril alone (n = 7559).The primary outcome
Efficacy of FolicAcid Therapy in Primary Prevention of Stroke Among Adults With Hypertension in China: The CSPPT Randomized Clinical Trial. Uncertainty remains about the efficacy of folicacid therapy for the primary prevention of stroke because of limited and inconsistent data.To test the primary hypothesis that therapy with enalapril and folicacid is more effective in reducing first stroke than enalapril alone among Chinese adults with hypertension.The China Stroke Primary Prevention Trial (...) , a randomized, double-blind clinical trial conducted from May 19, 2008, to August 24, 2013, in 32 communities in Jiangsu and Anhui provinces in China. A total of 20,702 adults with hypertension without history of stroke or myocardial infarction (MI) participated in the study.Eligible participants, stratified by MTHFR C677T genotypes (CC, CT, and TT), were randomly assigned to receive double-blind daily treatment with a single-pill combination containing enalapril, 10 mg, and folicacid, 0.8 mg (n = 10,348
Pre-conception FolicAcid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other FolicAcid-Sensitive Congenital Anomalies Pre-conception FolicAcid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other FolicAcid-Sensitive Congenital Anomalies - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 37, Issue 6, Pages 534 (...) –549 Pre-conception FolicAcid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other FolicAcid-Sensitive Congenital Anomalies PRINCIPAL AUTHOR, x R. Douglas Wilson , MD Calgary AB x GENETICS COMMITTEE x R. Douglas Wilson , MD (Chair) x R. Douglas Wilson , x François Audibert , MD x François Audibert , x Jo-Ann Brock , MD x Jo-Ann Brock , x June Carroll , MD x June Carroll , x Lola Cartier , MSc x Lola Cartier , x Alain Gagnon , MD x Alain Gagnon
Effect of Maternal Multiple Micronutrient vs Iron-FolicAcid Supplementation on Infant Mortality and Adverse Birth Outcomes in Rural Bangladesh: The JiVitA-3 Randomized Trial. Maternal micronutrient deficiencies may adversely affect fetal and infant health, yet there is insufficient evidence of effects on these outcomes to guide antenatal micronutrient supplementation in South Asia.To assess effects of antenatal multiple micronutrient vs iron-folicacid supplementation on 6-month infant (...) -folicacid alone, taken daily from early pregnancy to 12 weeks postpartum.The primary outcome was all-cause infant mortality through 6 months (180 days). Prespecified secondary outcomes in this analysis included stillbirth, preterm birth (<37 weeks), and low birth weight (<2500 g). To maintain overall significance of α = .05, a Bonferroni-corrected α = .01 was calculated to evaluate statistical significance of primary and 4 secondary risk outcomes (.05/5).Among the 22,405 pregnancies in the multiple
FolicAcid USE OF FOLICACID IN PREGNANCY 0344 892 0909 USE OF FOLICACID IN PREGNANCY (Date of issue: February 2018 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Folicacid (pteroylglutamic acid/PGA) is a synthetic derivative (...) of the water-soluble form of vitamin B9 (also known as folate). It requires metabolism to dihydrofolic acid and then to its biologically active form tetrahydrofolate. Folate is necessary for the production of blood cells and DNA. Folicacid is used in the treatment of nutritional megaloblastic anaemias and prophylactically in individuals at risk of deficiency e.g. due to chronic haemolysis or renal dialysis. During pregnancy folate requirements are increased 5- to 10-fold and pregnant women are therefore
Folicacid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as an antimetabolite due to its antagonistic effect on folicacid metabolism. Many patients treated with MTX experience mucosal, gastrointestinal, hepatic or haematologic side effects. Supplementation with folic (...) or folinic acid during treatment with MTX may ameliorate these side effects.To identify trials of supplementation with folicacid or folinic acid during MTX therapy for rheumatoid arthritis and to assess the benefits and harms of folicacid and folinic acid (a) in reducing the mucosal, gastrointestinal (GI), hepatic and haematologic side effects of MTX, and (b) whether or not folic or folinic acid supplementation has any effect on MTX benefit.We originally performed MEDLINE searches, from January 1966
Association between maternal use of folicacid supplements and risk of autism spectrum disorders in children. Prenatal folicacid supplements reduce the risk of neural tube defects in children, but it has not been determined whether they protect against other neurodevelopmental disorders.To examine the association between maternal use of prenatal folicacid supplements and subsequent risk of autism spectrum disorders (ASDs) (autistic disorder, Asperger syndrome, pervasive developmental disorder (...) -not otherwise specified [PDD-NOS]) in children.The study sample of 85,176 children was derived from the population-based, prospective Norwegian Mother and Child Cohort Study (MoBa). The children were born in 2002-2008; by the end of follow-up on March 31, 2012, the age range was 3.3 through 10.2 years (mean, 6.4 years). The exposure of primary interest was use of folicacid from 4 weeks before to 8 weeks after the start of pregnancy, defined as the first day of the last menstrual period before conception
Cancer risk with folicacid supplements: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
The effect of folicacid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis The effect of folicacid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis The effect of folicacid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T (...) , Nigwekar SU, Gallagher MP, Cass A, Strippoli G, Perkovic V CRD summary The authors concluded that folicacid based homocysteine lowering therapy did not reduce cardiovascular events in people with kidney disease, and should not be used as a preventive treatment. Overall, this was a well-conducted review and the conclusion is likely to be reliable. Authors' objectives To evaluate the effect of folicacid based homocysteine lowering on cardiovascular outcomes in people with kidney disease. Searching